ClinicalTrials.gg
CompletedNCT06081166Updated May 22, 2025

A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin

A Phase 1 interventional study of Obicetrapib and Atorvastatin Calcium in Healthy Volunteers, sponsored by NewAmsterdam Pharma. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-22.

Sponsored by NewAmsterdam Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A study to evaluate impact of Obicetrapib on PK levels of Atorvastatin and Rosuvastatin

Read the detailed description

A Study to Evaluate the Effect of Daily Doses of Obicetrapib Tablets on the Pharmacokinetics of Atorvastatin Calcium Tablets or Rosuvastatin Calcium Tablets in Healthy Adult Subjects

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cohort 1 Healthy, non-smoking, male and female subjects, from 18 to 65 years of age Cohort 2 Healthy, non-smoking, male and female subjects of non-Asian origin, from 18 to 65 years of age
  2. ≥18.5 and ≤30 kg/m2
  3. Females may be of childbearing or non-:

    • Childbearing potential:

      o Physically capable of becoming pregnant

    • Non-childbearing potential:

      • Surgically sterile (i.e., both ovaries removed, uterus removed, or bilateral tubal ligation); and/or
      • (no menstrual period for at least 12 consecutive months without any other medical cause and FSH and LH values consistent with being postmenopausal).
  4. Willing to use acceptable, effective methods of .
  5. Able to tolerate venipuncture.
  6. Be informed of the nature of the study and give written consent prior to any study procedure

Exclusion criteria

Exclusion Criteria:

  1. Known history or presence of neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  2. Known or suspected carcinoma.
  3. Known history or presence of or idiosyncratic reaction to atorvastatin, rosuvastatin, obicetrapib, or any other drug substances with similar activity.
  4. Known history or presence of chronic infectious disease, system disorders, organ dysfunction especially hypothyroidism, stroke or , myopathy, rhabdomyolysis, renal or hepatic disorders, diabetes, or obesity which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  5. Known history or presence of clinically significant lactose, galactose, or fructose intolerance.
  6. Subjects of Asian origin (Cohort 2 only).
  7. History of malabsorption within the last year or presence of clinically significant gastrointestinal (GI) disease.
  8. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
  9. History of drug or alcohol addiction requiring treatment.
  10. Positive test result for , surface antigen, or antibody.
  11. Positive test result for urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and tricyclic antidepressants) or urine cotinine.
  12. Difficulty consuming standard meals.
  13. Use of tobacco or nicotine-containing products within 6 months prior to drug administration.
  14. Females who:

    • Have used implanted, injected, intravaginal, or intrauterine hormonal within 6 months prior to drug administration;
    • Have used oral or transdermal hormonal contraceptives within 21 days prior to drug administration;
    • Are pregnant (serum hCG consistent with pregnancy); or
    • Are breast-feeding.
  15. Donation or loss of whole blood (including clinical trials):

    • ≥50 mL and \<500 mL within 30 days prior to drug administration;
    • ≥500 mL within 56 days prior to drug administration.
  16. Participation in a clinical trial that involved administration of an medicinal product within 30 days prior to drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results.
  17. On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet).
  18. Have had a tattoo or body piercing within 30 days prior to drug administration.
  19. Have clinically significant findings in vital signs measurements.
  20. Have clinically significant findings in a 12-lead .
  21. Have clinically significant abnormal laboratory values.
  22. Have significant diseases.
  23. Have clinically significant findings from a physical examination.
  24. Use of any of the following within 30 days prior to drug administration:

    • Anticoagulants
    • Anti-fungals (e.g., voriconazole, itraconazole)
    • Anti-virals
    • Capmatinib
    • Cholestyramine
    • Colchicine
    • Cyclosporine
    • Darolutamide
    • Digoxin
    • Drugs known to induce/inhibit hepatic drug metabolism or alter GI pH/movement (e.g., omeprazole, ranitidine)
    • Fostamatinib
    • Inducers and inhibitors of
    • Inducers and inhibitors of breast cancer resistant protein
    • Inducers and inhibitors of OATP1B1/OATP1B3
    • Inducers and inhibitors of P-glycoprotein)
    • Macrolide antibiotic medications (e.g., erythromycin)
    • Niacin
    • Regorafenib
    • Statins
    • Tafamidis
    • Teriflunomide
    • Drugs that decrease levels of endogenous hormones (e.g., ketoconazole, spironolactone, cimetidine)
    • Febuxostat
    • Fibrates (e.g., fenofibrate, gemfibrozil)
    • Warfarin
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Active comparator
    obicetrapib + atorvastatin

    Obicetrapib 10 mg tablets daily from Days 1-17 plus atorvastatin calcium 80 mg tablets on Day -4 and Day 12

    Drug: Obicetrapib · Drug: Atorvastatin Calcium

  • Active comparator
    obicetrapib + rosuvastatin

    Obicetrapib 10 mg tablets daily from Days 1-17 plus rosuvastatin calcium 40 mg tablets on Day -4 and Day 12

    Drug: Obicetrapib · Drug: Rosuvastatin Calcium

Interventions

06

What researchers measure

Primary outcomes

  1. Measure atorvastatin/rosuvastatin levels in the blood

    Measure atorvastatin/rosuvastatin concentrations via various analytical methods

    Time frame: zero (0) to time of the last measurable analyte concentration (t), up to 22 days

07

Study locations

1 site
  • Mark M Feldman
    Toronto, Ontario M1S 3V6, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Dec 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2023
First posted
Oct 13, 2023
StartActual
Nov 11, 2023
Primary completionActual
Dec 2, 2023
CompletionActual
Jan 22, 2024
Last update
May 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06081166
Lead sponsor
NewAmsterdam Pharma
Collaborators
Pharma Medica Research, Inc.
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Nov 11, 2023
Primary completion
Dec 2, 2023
Completion
Jan 22, 2024
Last update
May 22, 2025

Study contacts

Mark M Feldman
principal investigator · Pharma Medica Research, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: TA-8995 · Atorvastatin · Rosuvastatin

Start the discussion